Oxford BioDynamics PLC (DE:LMQ)
FRANKFURT:LMQ
LMQ Stock Chart & Stats
€0.01
>-€0.01(-5.88%)
At close: 4:00 PM EST
€0.01
>-€0.01(-5.88%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00K
Market Cap
€8.36M
Enterprise Value€7.66M
Total Cash (Recent Filing)€1.39M
Total Debt (Recent Filing)€5.11M
Price to Earnings (P/E)―
Beta-8.44
Next Earnings
Jan 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding4,290,911,000
10 Day Avg. Volume0
30 Day Avg. Volume4,000
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€26.55K
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthMaterial top-line expansion indicates growing commercial traction for OBD’s offerings. Sustained revenue growth over multiple periods supports scale-up of operations, strengthens negotiating power with partners, and creates scope to reinvest in product development and validation over the next 2–6 months.
Proprietary EpiSwitch PlatformA unique, platform-based technology that detects 3D genomic signatures creates a durable competitive advantage. Platform repeatability enables multiple diagnostic products and services, builds technical barriers to entry, and supports recurring revenue from assay development and validation engagements.
Diversified Revenue PathwaysMultiple monetization routes (own tests, fee-for-service biomarker work, and licensing/milestones) reduce single-product dependence. This structural revenue mix increases resilience to single-market setbacks and creates options for non-dilutive milestone or royalty income as products mature.
Bears Say
Persistent Negative MarginsOngoing negative gross and EBIT margins indicate the business has not yet achieved sustainable unit economics. Without margin improvement, continued top-line growth may not translate into profitability, pressuring cash reserves and constraining long-term reinvestment capacity.
High LeverageA high debt-to-equity ratio raises persistent interest and covenant risk and reduces financial flexibility. In volatile biotech markets, elevated leverage increases the probability of restrictive financing terms or the need for dilutive equity to shore up the balance sheet.
Weak Cash Flow ProfileSignificant negative FCF growth and negative operating cash conversion suggest ongoing cash burn. This structural cash shortfall forces reliance on external funding, which can dilute shareholders or constrain execution timing for clinical validation and commercialization plans.
Oxford BioDynamics News
LMQ FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is €8.36M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 26, 2027 which is in 235 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Currently, no data Available
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in DE:LMQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---